Skip to main content
AI News List

List of AI News about drug discovery

Time Details
2026-11-20
12:11 UTC
Isomorphic Labs and Merck partner to design new cancer drug

According to Isomorphic Labs and a post by Demis Hassabis cited by X, Isomorphic Labs entered a strategic research collaboration with Merck to design a new cancer drug using frontier AI and Merck’s development expertise.

Source
2026-11-20
11:22 UTC
OpenAI unveils MedChemBench to assess AI drug design progress

According to OpenAI and a post by Greg Brockman on X, MedChemBench is a new benchmark showing frontier model progress in medicinal chemistry reasoning to help identify promising drug candidates.

Source
2026-11-20
11:09 UTC
OpenAI unveils MedChemBench to gauge AI drug design progress

According to OpenAI, MedChemBench is a new benchmark for AI reasoning in medicinal chemistry that demonstrates progress of its frontier models in helping scientists identify promising drug candidates.

Source
2026-11-17
04:06 UTC
Isomorphic Labs secures $5B to accelerate AI drug design

According to a post by Demis Hassabis on X, Isomorphic Labs raised $5B to advance AI-driven, first-principles drug design aimed at cutting time and cost in new medicine discovery.

Source
2026-10-28
02:30 UTC
Genie 4 adds sound, Anthropic moves into drug R&D, GPT-6.1 Terra debuts

According to The Rundown AI, Genie 4 introduces sound and interactive AI worlds, Anthropic begins in-house drug development, GPT-6.1 Terra enables editable product mockups, and Axiom’s AI swarm verifies the longest math proof.

Source
2026-10-27
12:27 UTC
Anthropic details early Claude progress in drug development

According to Anthropic’s research blog, the company partnered with six medicine developers and began in-house discovery to show how Claude supports multiple drug development stages.

Source
2026-10-22
09:39 UTC
Warp Sciences raises $215M to build AI robot labs for drug R&D

According to The Rundown AI, ex-OpenAI product chief Kevin Weil raised $215M for Warp Sciences to create labs where AI designs experiments and robots run them 24/7, starting with drug discovery toward scientific superintelligence.

Source
2026-09-18
04:41 UTC
Anthropic Launches biology lab to scale AI drug R&D

According to @CNBC, Anthropic set up a biology lab to advance AI-driven drug discovery, Reuters reports, signaling pharma partnerships and wet lab validation.

Source
2026-08-18
03:13 UTC
AI startup accelerates rare disease treatments

According to @CNBC, an AI startup helps rare disease families design custom therapies faster and cheaper, streamlining target discovery and trial design.

Source
2026-06-30
12:06 UTC
Anthropic Claude Science targets drug discovery

According to @CNBC, Anthropic unveiled Claude Science to speed drug discovery with generative models and wet lab partners, challenging OpenAI and Google.

Source
2026-06-24
09:45 UTC
AI Drug Discovery Boosts Life Sciences Stock

According to @CNBC, a life sciences firm’s unique data asset is a moat for AI drug discovery, lifting platform demand and margins as reported by CNBC.

Source
2026-06-17
12:32 UTC
GPT5.4 Boosts medicinal chemistry reaction

According to gdb, GPT-5.4 with Molecule.one’s Maria AI proposed and validated a better drug discovery reaction pathway.

Source
2026-06-03
13:56 UTC
GPT-Rosalind Boosts drug design with agentic tools

According to OpenAI... GPT-Rosalind adds GPT-5.5 agentic coding and tool use to accelerate drug discovery, analysis, design, and lab workflows at scale.

Source
2026-06-03
13:15 UTC
GPT Rosalind boosts drug discovery with GPT5.5

According to @OpenAI, GPT Rosalind now fuses GPT5.5 agentic coding and tools to speed drug discovery, analysis, design, and lab workflows for enterprises.

Source
2026-05-12
05:50 UTC
Isomorphic Labs Secures $2.1B to Turbocharge Drug Discovery

According to @demishassabis, Isomorphic Labs raised $2.1B to accelerate AI-driven drug discovery building on AlphaFold, expanding partnerships and pipelines.

Source
2026-04-16
16:36 UTC
OpenAI Life Sciences Models: Latest Podcast Analysis on Biology, Drug Discovery, and Translational Medicine

According to OpenAI on X, research lead Joy Jiao and product lead Yunyun Wang joined host Andrew Mayne on the OpenAI Podcast to detail how the new Life Sciences model series is being built for biology, drug discovery, and translational medicine. According to the OpenAI podcast post, the discussion highlights opportunities such as accelerating target identification, literature synthesis, and assay design, alongside challenges in model validation, safety, and regulatory alignment for clinical workflows. As reported by OpenAI, the team emphasizes domain-tuned training data, tool use with structured biochemical databases, and evaluation benchmarks grounded in wet-lab outcomes to ensure models deliver verifiable gains for pharma R&D and biotech pipelines. According to OpenAI, this focus positions the models for business impact in preclinical research, biomarker discovery, and translational study design, where time-to-insight and reproducibility are critical purchasing drivers for biopharma and CROs.

Source
2026-04-16
13:33 UTC
GPT-Rosalind Launch: OpenAI’s Frontier Model for Biology, Drug Discovery, and Translational Medicine – Latest Analysis

According to OpenAI (via @gdb on X), the company introduced GPT-Rosalind as a frontier reasoning model designed to support research across biology, drug discovery, and translational medicine, with the stated aim of accelerating science and improving human outcomes (as reported by Greg Brockman on X). According to the announcement, OpenAI plans to deploy GPT-Rosalind with multiple partners, signaling immediate applied use cases in target identification, pathway analysis, and hypothesis generation for preclinical R&D (according to OpenAI’s X post). As reported by the same source, the positioning of GPT-Rosalind indicates focus on domain-grounded reasoning and safety for life sciences workflows, which could reduce time-to-insight for biopharma teams and contract research organizations.

Source
2026-04-16
11:33 UTC
OpenAI Highlights How Advanced AI Accelerates Drug Discovery: 3 Ways to Cut Timelines by Years

According to OpenAI on X, drug development in the United States typically takes 10 to 15 years from target discovery to regulatory approval, and advanced AI can speed this up by expanding hypothesis space, revealing nonobvious connections, and improving early-stage decision making (source: OpenAI post, Apr 16, 2026). As reported by OpenAI, AI-driven literature synthesis, multi-omics analysis, and generative molecular design can reduce iteration cycles and prioritization errors in target identification and lead optimization, which creates business opportunities for biopharma to lower R&D costs and increase pipeline throughput. According to OpenAI, these capabilities help researchers move faster not only by efficiency gains but by enabling better hypotheses sooner, pointing to near-term advantages for partnerships between model providers and pharma in preclinical discovery.

Source
2026-04-16
11:33 UTC
OpenAI Unveils GPT-Rosalind: Latest Frontier Reasoning Model for Biology and Drug Discovery

According to OpenAI on X, GPT-Rosalind is a frontier reasoning model designed to support research in biology, drug discovery, and translational medicine. As reported by OpenAI, the model targets complex scientific workflows such as hypothesis generation, experimental design assistance, and literature synthesis across biomedical domains. According to OpenAI, this positioning suggests near-term applications for pharma R&D teams, biotech startups, and academic labs seeking accelerated target identification, assay optimization, and preclinical decision support. As stated by OpenAI, the emphasis on reasoning indicates a shift toward specialized, domain-tuned LLMs that can handle structured scientific tasks and cross-reference data sources, opening opportunities for workflow integration with electronic lab notebooks, cheminformatics platforms, and knowledge graphs.

Source
2026-04-08
09:17 UTC
DeepMind’s Demis Hassabis on the Path to AGI: Latest 2026 Analysis of AI for Science and Medicine

According to Demis Hassabis on X, his 20VC conversation with host Harry Stebbings focused on the path to AGI and concrete ways AI is accelerating science and medicine today, highlighting the UK’s deep tech talent and ecosystem advantages (source: Demis Hassabis on X, Apr 8, 2026; Harry Stebbings on X). As reported by 20VC via Harry Stebbings, the discussion positions frontier AI research—exemplified by Google DeepMind’s work—as a driver for breakthroughs in drug discovery and biomedical research, creating commercialization opportunities for biotech partnerships, AI-first R&D platforms, and healthcare productivity tools (source: Harry Stebbings on X). According to the public post, the episode underscores UK-based opportunities including talent concentration, research universities, and venture funding alignment for scaling AGI-adjacent startups in therapeutics, protein design, and clinical decision support (source: Demis Hassabis on X).

Source